Tonghua Dongbao Pharmaceutical Co. Ltd. (600867)
Market Open
10 Aug, 06:57
SSE SSE Primary ¥
8. 38
-0.04
-0.4751%
¥
14.59B Market Cap
- P/E Ratio
1% Div Yield
34.06M Volume
- Eps
¥ 8.42
Previous Close Want to track 600867 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
600867 trading today lower at ¥8.38, a decrease of -0.4751% from yesterday's close, completing a monthly increase of 4.0994% or ¥0.33. Over the past 12 months, 600867 stock gained 2.5704%.
600867 pays dividends to its shareholders, with the most recent payment made on Jun 05, 2026. The next estimated payment will be in In 9 months on Jun 05, 2027 for a total of ¥0.3.
The last earnings report, released on Apr 20, 2026, missed the consensus estimates by -0.04%. On average, the company has fell short of earnings expectations by -0.0133%, based on the last three reports.
Tonghua Dongbao Pharmaceutical Co. Ltd. has completed 15 stock splits, with the recent split occurring on May 25, 2018.
The company's stock is traded on one exchange.
600867 Chart
People also search for
Tonghua Dongbao Pharmaceutical Co. Ltd. (600867) FAQ
What is the stock price today?
The current price is ¥8.38.
On which exchange is it traded?
Tonghua Dongbao Pharmaceutical Co. Ltd. is listed on SSE.
What is its stock symbol?
The ticker symbol is 600867.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 1%.
What is its market cap?
As of today, the market cap is 14.59B.
Has Tonghua Dongbao Pharmaceutical Co. Ltd. ever had a stock split?
Tonghua Dongbao Pharmaceutical Co. Ltd. had 15 splits and the recent split was on May 25, 2018.
Tonghua Dongbao Pharmaceutical Co. Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Chun Sheng Leng CEO | SSE Exchange | CNE000000H87 ISIN |
| CN Country | 3,196 Employees | 5 Jun 2026 Last Dividend | 25 May 2018 Last Split | 30 Jun 1994 IPO Date |
Overview
Tonghua Dongbao Pharmaceutical Co., Ltd., established in 1985 and headquartered in Tonghua, China, positions itself at the forefront of pharmaceutical innovation and production, concentrating on addressing diabetes, endocrine disorders, and cardiovascular and cerebrovascular diseases. With a diversified operational framework, the company spans across three major industry segments: Pharmaceutical Industry, Building Materials Industry, and Real Estate Industry. This strategic diversification not only underscores its commitment to healthcare but also showcases its footprint in the building materials and real estate sectors, amplifying its influence across different economic sectors within China.
Products and Services
The company's products and services lineup is predominantly designed to cater to the needs of diabetic patients and those suffering from related medical conditions. Below is a detailed breakdown:
- Human Insulin Raw Materials and Injection: The core of their product range, providing essential diabetes management solutions through both raw materials for pharmaceutical production and ready-to-use insulin injections.
- Insulin Glargine Raw Materials and Injection: Offers a long-acting insulin solution for managing blood sugar levels, available in both raw material for manufacturing and finished injectable form.
- Insulin Aspart API and Injection: This provides a fast-acting insulin option, catering to immediate insulin needs post meals, available as Active Pharmaceutical Ingredient (API) and in pre-filled injections.
- Zhennaoning Capsules: A specialized pharmaceutical product aimed at managing cardiovascular and cerebrovascular diseases, enhancing the company's portfolio in addressing broader health concerns.
- Diabetes-Related Medical Devices: Complementing its pharmaceutical products, Tonghua Dongbao provides a range of medical devices, including insulin pens and needle injection systems, aimed at improving the quality of life for those managing diabetes.
- Blood Sugar Monitoring System: A critical tool for diabetes management, allowing patients to regularly check and manage their blood sugar levels with ease and accuracy.
- Online and Offline Patient Management System: An innovative approach to patient care, offering support and management solutions through both online platforms and offline services, enhancing accessibility and convenience for patients.
- Building Materials: Beyond its pharmaceutical and medical device offerings, Tonghua Dongbao extends its expertise into the building materials industry, although specific products in this category are not detailed in the description provided.
Contact Information
Address: Dongbao New Village, Tonghua, China, 134123
Phone: 86 43 5508 8025
Website: https://www.thdb.com
